Sequent Scientific Limited (SEQUENT.BO)
INR 136.85
(3.52%)
INR 136.85
(3.52%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 549.8 Million INR | 904.18% |
| 2022 | -464.48 Million INR | -107.28% |
| 2021 | 1.2 Billion INR | -45.02% |
| 2020 | 2.11 Billion INR | 15.35% |
| 2019 | 1.8 Billion INR | 44.22% |
| 2018 | 1.33 Billion INR | 29.94% |
| 2017 | 980.57 Million INR | 33.57% |
| 2016 | 540.22 Million INR | 22.72% |
| 2015 | 638.77 Million INR | 99.51% |
| 2014 | 114.11 Million INR | 80.75% |
| 2013 | -382.81 Million INR | 299.54% |
| 2012 | -106.97 Million INR | -121.92% |
| 2011 | 475.58 Million INR | 126.48% |
| 2010 | -1.45 Billion INR | -270.84% |
| 2009 | 850.7 Million INR | 7763.96% |
| 2008 | -11.1 Million INR | -112.95% |
| 2007 | 85.73 Million INR | -33.11% |
| 2006 | 126.57 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 427.3 Million INR | 41.41% |
| 2023 FY | - INR | 904.18% |
| 2023 Q1 | -74.43 Million INR | 74.84% |
| 2023 Q2 | 167.79 Million INR | 325.43% |
| 2023 Q3 | 244.69 Million INR | 45.83% |
| 2023 Q4 | 342.57 Million INR | 40.0% |
| 2022 Q2 | 37.81 Million INR | 26.33% |
| 2022 Q3 | 141.9 Million INR | 275.3% |
| 2022 FY | - INR | -107.28% |
| 2022 Q4 | -295.82 Million INR | -308.47% |
| 2022 Q1 | 29.93 Million INR | -91.41% |
| 2021 Q4 | 348.51 Million INR | -12.63% |
| 2021 Q2 | 204.15 Million INR | -10.56% |
| 2021 FY | - INR | -45.02% |
| 2021 Q3 | 398.88 Million INR | 95.39% |
| 2021 Q1 | 228.26 Million INR | -42.61% |
| 2020 FY | - INR | 15.35% |
| 2020 Q4 | 397.72 Million INR | -40.93% |
| 2020 Q3 | 673.29 Million INR | 15.42% |
| 2020 Q2 | 583.32 Million INR | 24.04% |
| 2020 Q1 | 470.25 Million INR | 9.19% |
| 2019 Q3 | 509.67 Million INR | 18.17% |
| 2019 Q2 | 431.29 Million INR | 8.49% |
| 2019 Q1 | 397.54 Million INR | 7.26% |
| 2019 Q4 | 430.66 Million INR | -15.5% |
| 2019 FY | - INR | 44.22% |
| 2018 Q1 | 243.3 Million INR | 12.43% |
| 2018 Q4 | 370.64 Million INR | -1.62% |
| 2018 Q3 | 376.73 Million INR | 24.84% |
| 2018 Q2 | 301.77 Million INR | 24.03% |
| 2018 FY | - INR | 29.94% |
| 2017 Q2 | 254.96 Million INR | 36.36% |
| 2017 FY | - INR | 33.57% |
| 2017 Q1 | 186.97 Million INR | -69.84% |
| 2017 Q3 | 221.99 Million INR | -12.93% |
| 2017 Q4 | 216.4 Million INR | -2.52% |
| 2016 Q4 | 619.96 Million INR | 394.95% |
| 2016 Q2 | 222.26 Million INR | 55.82% |
| 2016 FY | - INR | 22.72% |
| 2016 Q1 | 142.63 Million INR | 84.96% |
| 2016 Q3 | 125.25 Million INR | -43.64% |
| 2015 Q1 | 210.86 Million INR | -71.66% |
| 2015 FY | - INR | 99.51% |
| 2015 Q4 | 77.12 Million INR | -47.09% |
| 2015 Q3 | 145.75 Million INR | -42.51% |
| 2015 Q2 | 253.52 Million INR | 20.23% |
| 2014 FY | - INR | 80.75% |
| 2014 Q4 | 744.16 Million INR | 1147.34% |
| 2014 Q3 | 59.66 Million INR | 210.93% |
| 2014 Q2 | -53.78 Million INR | -157.42% |
| 2014 Q1 | 93.65 Million INR | 214.16% |
| 2013 Q3 | 118.51 Million INR | 32.34% |
| 2013 Q1 | 65.95 Million INR | 132.27% |
| 2013 Q4 | -82.04 Million INR | -169.22% |
| 2013 FY | - INR | 299.54% |
| 2013 Q2 | 89.55 Million INR | 35.79% |
| 2012 Q2 | 80.19 Million INR | 345.98% |
| 2012 FY | - INR | -121.92% |
| 2012 Q1 | -32.6 Million INR | 0.0% |
| 2012 Q3 | 18.42 Million INR | -77.03% |
| 2012 Q4 | -204.37 Million INR | -1209.5% |
| 2011 FY | - INR | 126.48% |
| 2010 FY | - INR | -270.84% |
| 2009 FY | - INR | 7763.96% |
| 2008 FY | - INR | -112.95% |
| 2007 FY | - INR | -33.11% |
| 2006 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.603% |
| NATCO Pharma Limited | 18.79 Billion INR | 97.075% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 88.245% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -27.778% |
| Achyut Healthcare Limited | 524 Thousand INR | -104823.664% |
| Ajanta Pharma Limited | 12.56 Billion INR | 95.624% |
| Alkem Laboratories Limited | 24.19 Billion INR | 97.728% |
| Alpa Laboratories Limited | 86.12 Million INR | -538.36% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 94.283% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 76.672% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 99.11% |
| Bajaj HealthCare Limited | 444.51 Million INR | -23.685% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 62.827% |
| Brooks Laboratories Limited | 41.72 Million INR | -1217.581% |
| Divi's Laboratories Limited | 25.43 Billion INR | 97.838% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 99.377% |
| Eris Lifesciences Limited | 6.98 Billion INR | 92.13% |
| FDC Limited | 4.4 Billion INR | 87.509% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 95.153% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 91.989% |
| Granules India Limited | 8.6 Billion INR | 93.61% |
| Gufic Biosciences Limited | 1.48 Billion INR | 62.864% |
| Hester Biosciences Limited | 539.47 Million INR | -1.915% |
| Indoco Remedies Limited | 2.64 Billion INR | 79.23% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 91.987% |
| Ipca Laboratories Limited | 13.29 Billion INR | 95.866% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -69.975% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 764.596% |
| Lasa Supergenerics Limited | -65.08 Million INR | 944.806% |
| Laurus Labs Limited | 8 Billion INR | 93.133% |
| Lupin Limited | 36.96 Billion INR | 98.513% |
| Mankind Pharma Limited | 28.09 Billion INR | 98.043% |
| Medicamen Biotech Limited | 245.66 Million INR | -123.805% |
| Medico Remedies Limited | 150.37 Million INR | -265.612% |
| Megasoft Limited | 284.73 Million INR | -93.095% |
| Piramal Pharma Limited | 13.05 Billion INR | 95.789% |
| RPG Life Sciences Limited | 1.28 Billion INR | 57.097% |
| Sigachi Industries Limited | 883.39 Million INR | 37.763% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 114.735% |
| Unichem Laboratories Limited | 742.35 Million INR | 25.938% |
| Wanbury Limited | 985.49 Million INR | 44.21% |
| Windlas Biotech Limited | 781.72 Million INR | 29.668% |
| ZIM Laboratories Limited | 462.09 Million INR | -18.979% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 99.022% |
| Procter & Gamble Health Limited | 3.01 Billion INR | 81.761% |
| Amrutanjan Health Care Limited | 682.53 Million INR | 19.448% |
| Bal Pharma Limited | 345.59 Million INR | -59.089% |
| Strides Pharma Science Limited | 3.76 Billion INR | 85.396% |
| Venus Remedies Limited | 711.8 Million INR | 22.759% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 85.937% |
| Nectar Lifesciences Limited | 1.56 Billion INR | 64.842% |
| Shilpa Medicare Limited | 2.58 Billion INR | 78.756% |
| Aarti Drugs Limited | 3.24 Billion INR | 83.076% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 78.907% |
| Suven Life Sciences Limited | -992.78 Million INR | 155.38% |
| Ind-Swift Limited | 1.06 Billion INR | 48.379% |
| Valiant Laboratories Limited | 12.73 Million INR | -4215.88% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 94.11% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 119.483% |
| Themis Medicare Limited | 562.6 Million INR | 2.276% |
| Hikal Limited | 2.69 Billion INR | 79.578% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 98.43% |
| Novartis India Limited | 1.26 Billion INR | 56.685% |
| Wockhardt Limited | 1.08 Billion INR | 49.093% |
| Jubilant Pharmova Limited | 8 Billion INR | 93.133% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -4109.156% |
| Neuland Laboratories Limited | 4.74 Billion INR | 88.421% |
| Morepen Laboratories Limited | 1.72 Billion INR | 68.145% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -91.285% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -214.268% |